Effects of glucagon-like peptide-1 receptor agonists and dual glucagon-like peptide-1 receptor agonists/glucose-dependent insulinotropic polypeptide on liver stiffness and steatosis evaluated through Fibroscan®: a systematic review and meta-analysis
Diabetes medications called GLP-1 agonists measurably shrink fatty liver and reduce liver scarring in patients with metabolic disease.
This meta-analysis of 5 studies (9 trials, 554 treated patients) demonstrates that GLP-1 receptor agonists and dual GLP-1/GIP agonists significantly reduce liver stiffness and steatosis as measured by Fibroscan elastography in MASLD patients. These findings provide quantitative evidence supporting incretin therapy for the hepatic component of cardiometabolic disease.
What the study was
- Study design
- Systematic review and meta-analysis of RCTs and case-control studies
- Population
- MASLD patients with obesity/T2DM; 554 treated patients + 270 controls across 5 studies/9 trials
- Sample size
- 824
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Intern Emerg Med
Why it surfaced
Meta-analysis of RCTs confirming GLP-1RA/dual GIP efficacy on Fibroscan-measured liver outcomes in MASLD. Directly extends evidence base for incretin drugs beyond glycemic control into hepatic fibrosis/steatosis — a clinically important endpoint given MASLD epidemic.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.